Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New peptide could be effective treatment for triple negative breast cancer

01.03.2011
Obese population more at risk for this type of cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

The leptin receptor antagonist peptide, developed by researchers Laszlo Otvos and Eva Surmacz, could become an attractive option for triple negative breast cancer treatment, especially in the obese patient population. The researchers published their findings online in the European Journal of Cancer.

According to the researchers, triple-negative breast cancers—which represent 10 percent of all mammary tumors—are characterized by the aggressive traits that is often found in younger women and have been associated with poor prognosis.

"Obesity increases the risk for triple-negative breast cancer development," said Surmacz, an associate research professor in biology at Temple. "Because triple-negative breast cancer patients are unresponsive to current targeted therapies and other treatment options are only partially effective, new pharmacological modalities are urgently needed."

Leptin, a protein that is always elevated in obese individuals and is higher in women than in men, can act locally within the body and promote cancer development by inducing the survival and growth of tumor cells, counteracting the effects of cancer therapies, and promoting metastasis. Previous studies by Surmacz suggested that leptin levels are significantly higher in aggressive breast tumors than in normal breast tissue.

In their study, the researchers examined if the leptin receptor was a viable target for the treatment of this type of cancer. It has been shown that in human triple negative breast cancer tissues, the leptin receptor was expressed in 92 percent and leptin in 86 percent of cases.

Using a mouse model of triple negative breast cancer, they tested the new leptin receptor antagonist peptide and compared it to conventional chemotherapy. The leptin receptor antagonist peptide extended the average survival time by 80 percent, compared to 21 percent for chemotherapy. The peptide was found to be non-toxic even up to the highest dose administered, said Sumacz.

"If this peptide, with its advantageous administration route and safety profile, can be developed as a drug it could be a useful addition to the existing oncology drug repertoire against various forms of cancer, including breast, brain, prostate and colon cancers," said Sumacz.

The study was partially funded by the Pennsylvania Department of Health.

Otvos and Surmacz are inventors on an international patent application covering this peptide and analogues for the treatment of various cancers, arthritis and autoimmune disease forms. The patent is owned by Temple University. Start-up Peptherx, Inc has an exclusive option to negotiate a license to these compounds from Temple University. Peptherx, Inc is a therapeutic peptide company focused on designing, screening, and developing synthetic peptide modulators of adipokine signaling for the treatment of cancer, inflammatory/autoimmune and metabolic diseases.

Copies of this study are available to working journalists and may be obtained by contacting Preston M. Moretz in Temple's Office of University Communications at pmoretz@temple.edu.

Preston M. Moretz | EurekAlert!
Further information:
http://www.temple.edu

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>